Andreas Lindauer

943 total citations
19 papers, 775 citations indexed

About

Andreas Lindauer is a scholar working on Oncology, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Andreas Lindauer has authored 19 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Andreas Lindauer's work include Drug Transport and Resistance Mechanisms (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). Andreas Lindauer is often cited by papers focused on Drug Transport and Resistance Mechanisms (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Chemotherapy-induced cardiotoxicity and mitigation (3 papers). Andreas Lindauer collaborates with scholars based in Germany, United States and United Kingdom. Andreas Lindauer's co-authors include Ulrich Jaehde, Jeroen Elassaiss‐Schaap, Rik de Greef, Uwe Fuhr, Friederike Kanefendt, Matthias Scheffler, Oxana Doroshyenko, Jürgen Wolf, Bernhard K. Keppler and Christian G. Hartinger and has published in prestigious journals such as Clinical Pharmacology & Therapeutics, Clinical Pharmacokinetics and Journal of Pharmaceutical and Biomedical Analysis.

In The Last Decade

Andreas Lindauer

18 papers receiving 762 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andreas Lindauer Germany 10 506 188 151 140 78 19 775
Nicola Dobbs United Kingdom 15 378 0.7× 367 2.0× 118 0.8× 95 0.7× 37 0.5× 26 899
Prabhu Rajagopalan United States 17 360 0.7× 365 1.9× 98 0.6× 252 1.8× 40 0.5× 51 1.1k
Marek Mirowski Poland 18 549 1.1× 459 2.4× 96 0.6× 64 0.5× 64 0.8× 106 1.1k
Sihem Ait‐Oudhia United States 17 336 0.7× 389 2.1× 47 0.3× 136 1.0× 123 1.6× 40 1.1k
Lianshan Zhang China 18 339 0.7× 352 1.9× 107 0.7× 170 1.2× 23 0.3× 38 843
M. Ravic United Kingdom 14 398 0.8× 299 1.6× 77 0.5× 92 0.7× 57 0.7× 36 973
Pierre Bischoff France 19 336 0.7× 455 2.4× 220 1.5× 119 0.8× 37 0.5× 39 1.0k
Michela Guardascione Italy 16 336 0.7× 331 1.8× 58 0.4× 195 1.4× 45 0.6× 37 847
Diane E. Gingrich United States 15 251 0.5× 350 1.9× 226 1.5× 101 0.7× 26 0.3× 25 678
Vijay Shahani Canada 11 246 0.5× 369 2.0× 115 0.8× 64 0.5× 28 0.4× 19 711

Countries citing papers authored by Andreas Lindauer

Since Specialization
Citations

This map shows the geographic impact of Andreas Lindauer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Lindauer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Lindauer more than expected).

Fields of papers citing papers by Andreas Lindauer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Lindauer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Lindauer. The network helps show where Andreas Lindauer may publish in the future.

Co-authorship network of co-authors of Andreas Lindauer

This figure shows the co-authorship network connecting the top 25 collaborators of Andreas Lindauer. A scholar is included among the top collaborators of Andreas Lindauer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andreas Lindauer. Andreas Lindauer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Lindauer, Andreas, et al.. (2024). Exposure‐Efficacy Analysis and Dopamine D2 Receptor Occupancy in Adults with Schizophrenia after Treatment with the Monthly Intramuscular Injectable Risperidone ISM. The Journal of Clinical Pharmacology. 65(3). 350–360. 2 indexed citations
3.
Rodríguez‐Pascau, Laura, Sílvia Pascual, Sonia Poli, et al.. (2024). Clinical pharmacokinetics of leriglitazone and a translational approach using PBPK modeling to guide the selection of the starting dose in children. CPT Pharmacometrics & Systems Pharmacology. 13(6). 982–993. 2 indexed citations
4.
5.
Äbelö, Angela, et al.. (2019). Concentration–QT Modeling Following Inhalation of the Novel Inhaled Phosphodiesterase‐4 Inhibitor CHF6001 in Healthy Volunteers Shows an Absence of QT Prolongation. CPT Pharmacometrics & Systems Pharmacology. 8(7). 460–468. 6 indexed citations
6.
Lindauer, Andreas, Christian Laveille, & Armel Stockis. (2017). Time-to-Seizure Modeling of Lacosamide Used in Monotherapy in Patients with Newly Diagnosed Epilepsy. Clinical Pharmacokinetics. 56(11). 1403–1413. 4 indexed citations
7.
Elassaiss‐Schaap, Jeroen, Andreas Lindauer, Alexandre Sostelly, et al.. (2016). Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma. CPT Pharmacometrics & Systems Pharmacology. 6(1). 29–39. 65 indexed citations
8.
Lindauer, Andreas, et al.. (2016). Translational Pharmacokinetic/Pharmacodynamic Modeling of Tumor Growth Inhibition Supports Dose-Range Selection of the Anti-PD-1 Antibody Pembrolizumab. CPT Pharmacometrics & Systems Pharmacology. 6(1). 11–20. 83 indexed citations
9.
Elassaiss‐Schaap, Jeroen, et al.. (2016). Using Model-Based “Learn and Confirm” to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial. CPT Pharmacometrics & Systems Pharmacology. 6(1). 21–28. 91 indexed citations
10.
Kraff, Stefanie, Andreas Lindauer, Markus Joerger, Salvatore J. Salamone, & Ulrich Jaehde. (2015). Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel. Therapeutic Drug Monitoring. 37(6). 725–732. 19 indexed citations
11.
Kalayda, Ganna V., Andreas Lindauer, Michael R. Reithofer, et al.. (2012). Effect of reactivity on cellular accumulation and cytotoxicity of oxaliplatin analogues. JBIC Journal of Biological Inorganic Chemistry. 17(5). 699–708. 16 indexed citations
12.
Kanefendt, Friederike, Andreas Lindauer, K. Mross, Uwe Fuhr, & Ulrich Jaehde. (2012). Determination of soluble vascular endothelial growth factor receptor 3 (sVEGFR-3) in plasma as pharmacodynamic biomarker. Journal of Pharmaceutical and Biomedical Analysis. 70. 485–491. 7 indexed citations
13.
Kanefendt, Friederike, Andreas Lindauer, Matthias Scheffler, et al.. (2011). Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics. 50(9). 551–603. 183 indexed citations
14.
Lindauer, Andreas, Friederike Kanefendt, Dorota Tomalik‐Scharte, et al.. (2010). Pharmacokinetic/Pharmacodynamic Modeling of Biomarker Response to Sunitinib in Healthy Volunteers. Clinical Pharmacology & Therapeutics. 87(5). 601–608. 42 indexed citations
15.
Lindauer, Andreas, Christiane Eickhoff, Charlotte Kloft, & Ulrich Jaehde. (2010). Population Pharmacokinetics of High-Dose Carboplatin in Children and Adults. Therapeutic Drug Monitoring. 32(2). 159–168. 6 indexed citations
16.
Lentz, Frederike, Andreas Lindauer, Ralf A. Hilger, et al.. (2009). Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anti-Cancer Drugs. 20(2). 97–103. 210 indexed citations
17.
Lindauer, Andreas, Timo Siepmann, Reinhard Oertel, et al.. (2008). Pharmacokinetic/Pharmacodynamic Modelling of Venlafaxine. Clinical Pharmacokinetics. 47(11). 721–731. 15 indexed citations
18.
19.
Lindauer, Andreas, et al.. (2004). Synthesis of indolo-quinonediimine derivatives by the thermolysis of 5-(1-benzotriazolyl)-substituted spiro[2H-benzimidazole-2,1′-cyclohexane]. Journal of Chemical Research. 2004(7). 453–456. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicola Dobbs Breakdown of academic impact, for papers by Prabhu Rajagopalan Breakdown of academic impact, for papers by Marek Mirowski Breakdown of academic impact, for papers by Sihem Ait‐Oudhia Breakdown of academic impact, for papers by Lianshan Zhang Breakdown of academic impact, for papers by M. Ravic Breakdown of academic impact, for papers by Pierre Bischoff Breakdown of academic impact, for papers by Michela Guardascione Breakdown of academic impact, for papers by Diane E. Gingrich Breakdown of academic impact, for papers by Vijay Shahani
Rankless by CCL
2026